BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Ulthera Receives First-Ever FDA Clearance for Non-Invasive Lift of Skin on the Neck and Under the Chin


10/10/2012 7:28:57 AM

MESA, AZ--(Marketwire - October 10, 2012) -

Ulthera, Inc. -- a global, high-growth medical device company pioneering aesthetic and medical applications using its therapeutic ultrasound platform technology -- today announced that its ultrasound platform device, the Ulthera System, has received FDA clearance to non-invasively lift lax tissue on the neck and the submentum (under the chin).

This is the second lift indication that the System has received; the first cosmetic lift indication was granted in 2009, when the Ulthera System was cleared as a facial treatment with a specific indication for non-invasive eyebrow lift. To date, the Ulthera System remains the only energy-based device with an indication for lift.

The Ulthera System -- which combines time-honored ultrasound imaging with focused ultrasound therapy -- is used in Ultherapy, a face and neck treatment with well over 100,000 patient procedures performed worldwide.

"This latest validation of the Ulthera System and Ultherapy procedure is testament to the results our clinicians report globally," said Matthew Likens, president and CEO of Ulthera. "We know from our customers and their patients that sagging skin under the chin and on the neck is a significant issue. Patient demand for a non-invasive lift on the face and neck with just one treatment and no downtime is well established."

"As an FDA-cleared facial treatment for more than three years, many clinicians have noted results outside the indicated brow area," said principal investigator Jeffrey Kenkel, M.D., Professor and Vice-Chairman of Plastic Surgery at UT Southwestern Medical Center. "The ability to specifically claim lifting in another area, however, required solid quantitative data that would support noticeable and measurable results in these areas."

"This clearance for the neck and under the chin is just one in a series of many new clinical indications we are pursuing in the years ahead," Likens continued. "Utilizing our tried-and-true ultrasound technology, our customers can expect to see continued investment by Ulthera to expand our platform technology's treatment capabilities."

Photos "Before and After" the procedure are available for viewing: http://www.ultherapy.com/Ultherapy-Before-And-After-Photos

About Ulthera
Ulthera®, Inc. is a global, high-growth medical device company pioneering aesthetic and medical applications using its therapeutic ultrasound platform technology. The Ulthera® System is the first and only energy-based device to receive FDA clearance for a non-invasive aesthetic lift indication. It is used in a face and neck procedure known as Ultherapy®, which is cleared to lift skin on the brow, neck and under the chin. Founded in 2004 and based in Mesa, Ariz., Ulthera is a privately held company backed by top-tier venture capital firms, New Enterprise Associates and Apposite Capital. For more information, visit www.ultherapy.com.


Media Contact:
Susan Sorensen
650.342.8114
480.619.4069
Ulthera, Inc.
Email Contact

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES